Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia

Does treatment with the oral proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide lead to clinically meaningful reductions in low-density lipoprotein cholesterol in adults with heterozygous familial hypercholesterolemia?In this phase 3, randomized clinical trial including 303 adults with heterozygous familial hypercholesterolemia and stable background statin use, the percentage change in the level of low-density lipoprotein cholesterol at 24 weeks was clinically meaningful and significant in those treated with enlicitide (−58.2%) vs placebo (2.6%) (between-group difference, −59.4%).In adults with heterozygous familial hypercholesterolemia, enlicitide is an effective and well-tolerated treatment for lowering the level of low-density lipoprotein cholesterol.

Corresponding Author: Christie M. Ballantyne, MD, Texas Heart Institute at Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030 (cmb@bcm.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.